Loading
A phase 1/2 trial of Pembrolizumab in triple-negative breast cancer, renal cell carcinoma, ovarian cancer and head and neck squamous cell carcinoma, run by Scancell Ltd, now recruiting.
Modi-1 Moditope in Breast, Head and Neck, Ovarian, or Renal Cancer is a phase 1/2 interventional study registered as NCT05329532 by Scancell Ltd, with 168 participants planned, started 2022-04-07 and due to reach its primary completion in 2026-07-01. Interventions recorded: Modi-1 Moditope, Pembrolizumab and MicronJet600™ microneedle device (NanoPass).
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Triple-negative breast cancer (TNBC), Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Renal cell carcinoma, Head and neck squamous cell carcinoma, Triple-negative breast cancer (TNBC) and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Pembrolizumab, Immune checkpoint inhibitors and the tag pipeline.
Shares Scancell and the tag pipeline.
Shares Head and neck squamous cell carcinoma, Ovarian cancer, Triple-negative breast cancer (TNBC) and the tag pipeline.